Skip Navigation


JAC Advance Access originally published online on November 13, 2008
Journal of Antimicrobial Chemotherapy 2009 63(2):405-406; doi:10.1093/jac/dkn474
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
63/2/405    most recent
dkn474v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wei, Q.
Right arrow Articles by Lu, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wei, Q.
Right arrow Articles by Lu, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letters

dfrA27, a new integron-associated trimethoprim resistance gene from Escherichia coli

Quhao Wei{dagger}, Xiaofei Jiang{dagger}, Zehua Yang, Nan Chen, Xiaoyun Chen, Gang Li and Yuan Lu*

Department of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Central Urumqi Road, Shanghai, China

* Corresponding author. Tel/Fax: +86-21-62498118; E-mail: yuanlu@hsh.stn.sh.cn

Keywords: dihydrofolate reductase , mobile genetic elements , gene cassettes

The first 10% of the full text of this article appears below.

Sir,

Trimethoprim is a synthetic antibiotic. With its structure similar to that of folic acid, trimethoprim is a competitive inhibitor of dihydrofolate reductase (DHFR).1 Owing to its high concentration in urine that is sufficient to inhibit most urinary pathogens, trimethoprim alone or combined with sulphonamides has been widely used in the treatment of urinary tract infections.2 Bacterial resistance to trimethoprim can be inherent or acquired. The most common mechanism involves expressing trimethoprim insensitive variants of DHFR within mobile genetic elements, such as plasmids, transposons and integrons.1 Up to now, more than 22 different trimethoprim resistance dfrA genes have been reported and . . . [Full Text of this Article]


   Funding
 

   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?